2025³â 08¿ù 07ÀÏ ¸ñ¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > Àαⴺ½º

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýȰ

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óǰ

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
 
¸ðµÎ 92546°³ÀÇ ´º½º°¡ °Ë»öµÇ¾ú½À´Ï´Ù.



ÅÂÇ×È£, MBC ¡®¸Þ¸® ųÁî ÇÇÇᯠÃ⿬

ºÎÇü»ç·Î º¯½Å, Á¶·Â»ç¸Á »ç°Ç ÃßÀû
¹è¿ì ÅÂÇ×È£°¡ Áö³­ 1ÀÏ Ã¹ ¹æ¼ÛµÈ MBC ±ÝÅäµå¶ó¸¶ ‘¸Þ¸® ųÁî ÇÇÇÃ’(±âȹ ±Ç¼ºÃ¢ / ¿¬Ãâ ¹ÚÁØ¿ì / ±Øº» À̼ö¾Æ / Á¦ÀÛ ¹Ì½ºÅͷθǽº, ¹«ºùÇÈÃĽºÄÄÆÛ´Ï, ½ºÆ©µð¿À ¾ÈÀÚÀÏ·»)À» ÅëÇØ ½ÃûÀÚµé°ú ¸¸³µ´Ù.   ‘¸Þ¸® ųÁî ÇÇÇÃ’Àº Ä¡·á°¡ ºÒ°¡´ÉÇÑ È¯ÀÚµéÀÇ Á¶·Â »ç¸ÁÀ» µ½´Â ÀÇ»ç¿Í À̸¦ ÃßÀûÇÏ´Â Çü»çÀÇ À̾߱⸦ ±×¸° ¼­½ºÆæ½º µå¶ó¸¶´Ù.   ±Ø Áß ÅÂÇ×È£´Â ±¤¼ö´ëÀå żº(±èÅÂ¿ì ºÐ)°ú ÇÔ²² »ç°ÇÀ» ÂÑ´Â ‘ºÎÇü»ç’·Î ºÐÇØ, Á¶·Â »ç¸Á »ç°ÇÀÇ ½Çü¿¡ ´Ù°¡¼­±â À§ÇØ ÇöÀåÀ» ´©ºñ°í ´Ü¼­¸¦ ...

KGM, Áö´ÉÇüÀÚµ¿Â÷ºÎǰÁøÈï¿ø°ú ÀÚÀ²ÁÖÇà ±â¼úÇù·Â MOU

ÀÚÀ²ÁÖÇà °ü·Ã À¯·´ ¹ý±Ô ´ëÀÀÀº ¹°·Ð ¾ç»ê ±â¼ú È®º¸ ±â´ë
KG ¸ðºô¸®Æ¼(ÀÌÇÏ KGM)°¡ Áö´ÉÇüÀÚµ¿Â÷ºÎǰÁøÈï¿ø (ÀÌÇÏ ÁøÈï¿ø)°ú ÀÚÀ²ÁÖÇà ±â¼ú °³¹ß MOU¸¦ ü°áÇÏ°í »óÈ£Çù·ÂÇϱâ·Î Çß´Ù. Áö³­ 28ÀÏ(¿ù) ÁøÈï¿ø º»»ç(´ë±¸½Ã ´Þ¼º±º ¼ÒÀç)¿¡¼­ ¿­¸° MOU ü°á½Ä¿¡´Â KGM ±Ç¿ëÀÏ ±â¼ú¿¬±¸¼Ò ¼ÒÀå°ú ÁøÈï¿ø ¼­ÀçÇü ¿øÀåÀ» ºñ·ÔÇÑ °ü°èÀÚµéÀÌ Âü¼®Çß´Ù. ÁøÈï¿øÀº ÀÚÀ²ÁÖÇàÂ÷ µî Â÷¼¼´ë ÀÚµ¿Â÷ ±â¼úÀ» °³¹ßÇÏ´Â °ü·Ã ¾÷ü¿Í ¿¬±¸±â°üÀ» Áö¿øÇϱâ À§ÇØ 2014³â ¼³¸³µÈ ½ÃÇè Àü¹® ±â°üÀ¸·Î, °í¼Ó ÁÖȸ·Î, ¹ü¿ë ½ÃÇè·Î µî ´Ù¾çÇÑ Á¶°Ç¿¡¼­ÀÇ ÀÚµ¿Â÷ ÁÖÇà ½ÃÇè ¹× Ãæ°Ý ³»±¸ ½ÃÇè Àåºñ µîÀÇ ½Ã¼³ ¹× ½ÃÇè Àη ...

Novotech Report: How In-Vivo CAR-T May Reshape Cell Therapy Econo...
SYDNEY -- With in-vivo CAR-T therapies gaining global momentum, a new whitepaper from Novotech, a leading global full-service clinical Contract Research Organization (CRO) and scientific advisory company, offers insight into this next frontier of immunotherapy. In-Vivo CAR Therapies - Global Research and Development Landscape (2025) report explores the accelerating innovation in in-vivo CAR-T (Chimeric Antigen Receptor) technologies and their potential to reshape treatment across oncology, autoi ...
Çѱ¹ÀÇ Æú Æ÷Ã÷¡®ÃÖ¼ººÀ¡¯, ÇÒ¸®¿ìµå ¿µÈ­·Î Á¦À۵ȴ٠(2014-03-07)
LGÀüÀÚ, ¡®Ç¥Çö·Â Á¾°áÀÚ¡¯ °ÔÀÌ¹Ö ¸ð´ÏÅÍ °ø°³ (2017-08-25)
¾Æ´õ¿¡·¯-ÀÚ¶ó, Çѱ¹ ÃÖÃÊ Çù¾÷ ÇÁ·ÎÁ§Æ® °ø°³ (2021-12-16)
»ï¼ºÀüÀÚ, Á¦13ȸ Å罺ÅäÀÌ ¹®Çлó ½Ã»ó½Ä °³ÃÖ (2015-10-29)
LM, ±Û·Î¹ú °¡»óÀÚ»ê °Å·¡¼Ò ¡®ºñÆ®°Ù¡¯ »óÀå (2024-02-05)
¤¶óÀÎÄÚ¸®¾Æ, ¿ëÀÎÀÚ¿¬È޾縲 ¿¡ÄÚ¾îµåº¥Ã³ Àç°³Àå (2022-07-15)
KT¿¡¼­ °¡Á·µé°ú Áñ°Ì°í ½Å³ª´Â ¼ö¿äÀÏ º¸³»¼¼¿ä! (2015-05-26)
¡®ºò½º ij½Ãºñ ±³ÅëÄ«µå¡¯ ÇÑÁ¤ÆÇ À̸¶Æ®24 ´Üµ¶ Ãâ½Ã (2018-04-28)
ÅׯÈ, ¸ÅÁ÷ÇÚÁî ¼¼Æ® 5Á¾ Ưº°ÇÑ ±¸¸Å ÇýÅà Á¦°ø (2022-04-26)
³ó½Äǰ ¼öÃâ, Àü³â µ¿±â ´ëºñ 11.3% Áõ°¡ (2017-04-26)
´ëÇÑÇ×°ø, 5³â ¸¸¿¡ ¿ÀÀÌŸ ³ë¼± ¿îÇ× Àç°³ (2023-12-07)
KT DS ÅëÇÕ°üÁ¦½Ã½ºÅÛ, Çѱ¹SW¾ÆÅ°ÅØÆ® ¡®¿ì¼ö»ó¡¯ (2015-07-16)
Spesolimab meets primary and key secondary endpoint for prev... (2023-01-30)
Å縮¾Æ-¸¶½ºÅÍÄ«µå, °¡»ó Ä«µå B2B °áÁ¦ ¼Ö·ç¼Ç Ãâ½Ã Çù·Â (2023-11-29)
Ä÷³ºñ¾Æ, ³²ÁÖÇõ ¿©¸§ È­º¸ °ø°³ (2021-05-06)
¾ÆÀ̸¶ÀÌÆù Àü Á¦Ç° ÇöÀç °¡°Ý¼­ 15% Ãß°¡ ÇÒÀÎ (2023-01-18)
18.4ÀÎÄ¡ ´ëÈ­¸é ÅÂºí¸´ ¡®°¶·°½Ãºä¡¯ Ãâ½Ã (2016-02-16)
´ë±¸½Ã, '³»ÀÏ·Î' °ü±¤°´ À§ÇÑ Æ¯º° ÇÒÀÎÇýÅà (2015-12-18)
°Ç±¹´ë-Çѱ¹»ê¾÷Àη°ø´Ü, ¡®Ã»³â ÇØ¿Ü Ãë¾÷ ¸àÅ丵¡¯ (2023-11-05)
1Àΰ¡±¸ ¸ÂÃã ¡®°£ÆíÁ¶¸®¿ë³ª¹°¡¯ (2016-10-20)
°ÔÀÓ¹®È­ °¡Á·Ä·ÇÁ, °¡Á· È­ÇÕÀÇ µµ±¸·Î (2022-12-17)
ÇàÀÚºÎ, Á¦ÁÖµµ ÀÏÁÖÇÏ´Â ÀÚÀü°Å±æ °³Åë (2015-11-08)
Mary Kay Protects Critically Endangered Lemurs and Other Wil... (2022-12-09)
8¿ùºÎÅÍ È£³²¼± KTX Á¼® 30% ´Ã¾î³ª (2015-07-07)
°í1 Çлý Àẹ°áÇÙ ¼±Á¦Àû ¾à¹° Åõ¾à, ½ÅÁßÇØ¾ß (2017-03-20)
       [ÀÌÀü][1]....[1074][1075][1076][1077][1078][1079][1080][1081][1082]...[3702][´ÙÀ½]

°øÁö»çÇ×
´º½ºÁö ÇÑÀÚ Ç¥±â¿¡ ´ë¸¸½Ä À½Â÷ Ç¥±â '纽ÞÙó¢ ´Ï¿ì½ÃÁö' º´±â
º£³×ÇÁ·Ò º£³×ÀÎÅõ Áß¹® Ç¥±â 宝Ò¬ÜØÙÌ 宝Ò¬ì×öõ(ÜÄÒ¬ÜØÙÌ ÜÄ...
¹Ìµð¾î¾Æ¿ì¾î Mediaour ØÚ体ä²们 ØÚô÷ä²Ùú MO ¿¥¿À ØÚä² ØÚä²
¾Ë¸®¿ìºê Alliuv ä¹备: ä¹联êó备, ¾Ë¶ã Althle ä¹÷åìÌ
¾Ë¸®¾Ë Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øÃ¼ Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º : À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¹ÙÀÌ¿ÀÀÌ´Ï Bioini Áß¹® Ç¥±â ù±药研 ù±å·æÚ
¿À½ºÇÁ·Ò Ausfrom 奥ÞÙÜØÙÌ, À£ÇÁ·Ò Welfrom 卫ÜØÙÌ
¿¡³ÊÇÁ·Ò Enerfrom 额ÒöÜØÙÌ ¿¡³ÊÀ¯ºñ Eneruv 额Òöêó备
¾ËÇÁ·Ò Alfrom Áß¹® Ç¥±â ä¹尔ÜØÙÌ ä¹ì³ÜØÙÌ
 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇѰè¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, ÆÑ½º 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..